ALKERMES | ALKS - Ordinary Share Capital


ALKERMES reported $165.61M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Acadia Pharmaceuticals USD 169.18M 470K Dec/2025
ALKERMES USD 165.61M 503K Dec/2025
Amgen USD 539M 1000K Dec/2025
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 192.3M 201K Dec/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Coherus Biosciences USD 121.16M 4.92M Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Ionis Pharmaceuticals USD 161.97M 836K Dec/2025
J&J USD 2.41B 584K Sep/2025
Malin Corporation EUR 200K 0 Dec/2024
Merck USD 2.49B 15.79M Sep/2025
Minerva Neurosciences USD 1000 0 Sep/2024
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.1M 400K Dec/2025
Otsuka Holdings JPY 528.13M 0 Dec/2025
Ovoca Bio EUR 29.49M 18.43M Jun/2025
Pfizer USD 5.69B 1000K Sep/2025
Regeneron Pharmaceuticals USD 105.3M 1.1M Sep/2025
Vertex Pharmaceuticals USD 254M 0 Dec/2025